Actelion's Uptravi Approval To Shake Up Market
This article was originally published in Scrip
You may also be interested in...
Arena reported statistically and "clinically" significant results from its Phase II study for ralinepag in pulmonary arterial hypertension (PAH), driving its share price up by more than 40%, but details expected later this year or in 2018 are needed to shed more light on the data.
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.